ESMO 2026: Medidata’s Next-Gen AI Imaging Slashes Imaging Bottlenecks to Accelerate Life-Saving Cancer Trials

Company News
October 20, 2026

Madrid, Spain – October 20, 2026 – Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions, is building on its foundation of supporting the majority of global oncology drug approvals by advancing its re-engineered, AI-powered imaging solution at the European Society of Medical Oncology Congress 2026 (ESMO) in Madrid, Spain. Designed to directly address the primary cause of delays in solid tumor trials, Medidata Imaging integrates Medidata AI with direct feedback from clinical study teams. The result is a new standard for speed and precision that accelerates new therapy breakthroughs in oncology and other therapeutic areas.

Quantifiable Breakthroughs: AI-Delivered Precision and Speed 

Part of the Medidata Data Experience - which connects every stage of the clinical data lifecycle - Medidata Imaging is built on proprietary algorithms engineered to deliver immediate, measurable impact to trials by solving major pain points in oncology and other image-dependent studies, including:

  • Greater than 97% Accuracy: AI-powered algorithms deliver anatomy verification with considerably greater accuracy than industry benchmarks
  • 32% Faster Protected Health Information Redaction: An automated text detection algorithm eliminates the need for manual redaction
  • Quality Control Results in Minutes: Medidata Imaging will also soon include intelligent "patient similarity" quality control checks that validate follow-up-to-baseline consistency, the presence of IV/oral contrast, and proper field of view, delivering nearly immediate, actionable feedback to rapidly address imaging issues and avoid costly delays.

"Every delay in imaging review slows down life-saving cancer research," said Wayne Walker, senior vice president of Data Experience at Medidata. "Powered by a global, industry-leading dataset and refined by direct feedback from clinical study teams - our AI brings unprecedented accuracy and speed to imaging workflows. Because imaging determines success in over 90% of solid tumor studies, infusing our AI directly helps clinical teams move from scan to solution faster than ever.”

More AI-Driven Breakthrough Functions Ahead

The complexity of modern clinical trials, especially for cancer therapies, requires a continuous evolution in clinical research technology. Building on its strong foundation—which supported more than 95% of all oncology drug approvals in 2025 and was preferred two-to-one by clinical trial sites—Medidata is continuing to invest in cutting-edge imaging capabilities to further advance oncology trials.

Targeted for launch in 2027, these capabilities will include AI enhanced automated tumor detection with 2D and 3D volume assessments and an enhanced specialist interface. Taken together, these advancements will be another significant leap forward in connecting sponsors with the speed of AI-driven innovation.

Visitors to ESMO can experience Medidata Imaging first-hand at Booth #1050. Please visit Medidata Imaging, Medidata AI and the Data Experience for more information.